Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: A case report

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Mody, Kabir ^a   Strauss, Edward ^a   Lincer, Robert ^a   Frank, Richard C ^a  

^a NORWALK HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE;

AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CHOLECYSTECTOMY; CHOLECYSTITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIARRHEA; DRUG RESPONSE; ECHOGRAPHY; FATIGUE; GALLBLADDER CARCINOMA; GENE MUTATION; GENOTYPE; HEPATOJEJUNOSTOMY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PARTIAL HEPATECTOMY; PELVIS LYMPHADENECTOMY; PHYSICAL EXAMINATION; RASH; BIOSYNTHESIS; EXON; GALLBLADDER TUMOR; GENETICS; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; DEOXYCYTIDINE; DNA MUTATIONAL ANALYSIS; EXONS; GALLBLADDER NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MUTATION; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 77958016172     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-570     Document Type: Article

References (18)

1. Xiu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. The Oncologist 2010, 15:168-181. 10.1634/theoncologist.2009-0302, 20147507.
2. Gallardo J, Rubio B, Villanueva L, Barajas O. Gallbladder cancer, a different disease that needs individual trials. J Clin Oncol 2005, 23:7753-7754. 10.1200/JCO.2005.02.7524, 16234545.
3. Valle JW, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281. 10.1056/NEJMoa0908721, 20375404.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345. 10.1056/NEJMoa033025, 15269313.
5. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 [HER2]-positive advanced gastric cancer [abstract]. J Clin Oncol 2009, 27:18s.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Din K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966. 10.1200/JCO.2006.07.9525, 17452677.
7. Philip AP, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006, 24:3069-3074. 10.1200/JCO.2005.05.3579, 16809731.
8. Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, Kanzler S. Gemcitabine in combination with EGF-Receptor antibody (cetuximab) as a treatment of cholangiocarcioma: a case report. BMC Cancer 2006, 6:190. 10.1186/1471-2407-6-190, 1564184, 16846514.
9. Malka D, Trarbach T, Faroux L, Mendiboure J, de la Fouchardiere C, Viret F, Assenat E, Boucher E, Rosmorduc O, Greten T. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin [GEMOX] alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial [abstract]. J Clin Oncol 2009, 27:15s.
10. Frank RC. Fighting Cancer with Knowledge and Hope 2009, 39-42. New Haven: Yale University Press.
11. Ciardiello F, Giampaolo T. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174. 10.1056/NEJMra0707704, 18337605.
12. Gelibter A, Malaguti P, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Carboni F, Ettorre GM, Pellicciotta M, Giannarelli D, Terzoli E, Cognetti F, Milella M. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005, 104:1237-1245. 10.1002/cncr.21286, 16078261.
13. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, Ahumada M. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001, 12:1403-1406. 10.1023/A:1012543223020, 11762811.
14. Zhu AX, Meyerhardt JA, Blaszkowsy LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancer and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010, 11:48-54. 10.1016/S1470-2045(09)70333-X, 19932054.
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
16. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957. 10.1056/NEJMoa0810699, 19692680.
17. Gwak G-Y, Yoon J-H, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee H-S. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinoma. J Cancer Res Clin Oncol 2005, 131:649-62. 10.1007/s00432-005-0016-1, 16032426.
18. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 2006, 12:1680-1685. 10.1158/1078-0432.CCR-05-1692, 16551849.